Severe sepsis with multiple organ failure after hematopoietic stem cell transplantation (HSCT) results in extremely high morbidity and mortality. Recent studies have highlighted the importance of sepsis-induced activation of the coagulation system in the pathophysiology of severe sepsis. Activated protein C is an important modulator of coagulation and inflammatory derangements during severe sepsis. Low levels of protein C occur in severe sepsis and are predictive of poor outcome. Recombinant human activated protein C (drotrecogin alfa (activated)) was recently approved by the Food and Drug Administration (FDA) for severe sepsis. The phase III trial that resulted in the approval of this agent, however, enrolled a general sepsis population and excluded patients undergoing HSCT. We report a case of fulminant septic shock and multiple organ failure after HSCT that was treated with drotrecogin alfa (activated) in addition to standard therapy, and recovered. The high mortality rates of patients who develop severe sepsis after HSCT demand that new avenues of treatment be considered for this very highrisk patient population. This case illustrates the potential application of a novel therapeutic approach. Clinical trials are warranted to further investigate the safety and efficacy of drotrecogin alfa (activated) in patients with severe sepsis after HSCT.
or allogeneic hematopoietic stem cell transplantation (HSCT). [1] [2] [3] [4] [5] The sepsis syndrome results from a generalized inflammatory and procoagulant response to infection. 6 Activated protein C, an endogenous protein with antithrombotic, pro-fibrinolytic, and anti-inflammatory properties, is an important modulator of the coagulation and inflammatory derangements during severe sepsis. 7, 8 Low levels of protein C occur in severe sepsis and are predictive of poor outcome. 9, 10 Recombinant human activated protein C (drotrecogin alfa (activated)) (Eli Lilly, Indianapolis, IN, USA) was recently approved by the Food and Drug Administration (FDA) for severe sepsis.
11 To our knowledge, we report the first case of septic shock and multiple organ failure after allogeneic HSCT that was treated with recombinant human activated protein C (drotrecogin alfa (activated) in addition to standard therapy.
Case report
A 41-year-old female with chronic lymphocytic leukemia (CLL) was admitted to the ICU in December 2001 from the transplant ward within 10 h of admission to the hospital. At ICU admission she was in shock and multiple organ failure. Two weeks before hospital admission, she developed a dry cough that was treated with a 5-day course of azithromycin. On the day of admission, she complained of fever, right upper quadrant discomfort, generalized weakness and progressive dyspnea. Medications on hospital admission included cyclosporin, fluconazole, acyclovir, folic acid, lansoprazole, lorazepam, calcium carbonate, and multivitamins.
The patient was diagnosed with CLL characterized by de novo transformation to large cell lymphoma in June 2000 and was treated with six cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). She then underwent allogeneic T cell-depleted HSCT from her human leukocyte antigen (HLA)-identical sister in January 2001 after a conditioning regimen of cyclophosphamide, thiotepa and hyperfractionated total body irradiation. Her post-transplant course was complicated by graft failure and smoldering relapse of underlying disease. A second allogeneic HSCT from the same sister was performed in October 2001 after a nonmyeloablative conditioning regimen (fludarabine, melphalan and alemtuzumab). Her posttransplant course was complicated by an appendiceal abscess which improved with i.v. antibiotics. A bone marrow biopsy obtained 2 weeks before ICU admission showed normal trilineage hematopoiesis and no evidence of lymphoproliferative disorder.
On admission to the ICU, she was awake but lethargic with a blood pressure of 64/45 mm Hg, heart rate of 94 beats/min, respiratory rate of 24 breaths/min and temperature of 33.6°C. A Hickman catheter was present with no signs of erythema or purulence at the exit site. Her abdomen was soft but tender in the right upper quadrant with mild hepatomegaly and normoactive bowel sounds. There were no other significant abnormalities on physical examination.
Initial blood tests indicated a white blood cell count of 11 500/mm 3 with a differential count showing 92% neutrophils; a hemoglobin level of 9.4 g/dl; and a platelet count of 163 000/mm 3 . Prothrombin time was prolonged at 24 s with an international normalized ratio (INR) of 1.96 and the activated partial thromboplastin time was 31 s. D-dimer was elevated at 4.0 g/ml (normal, Ͻ0.5) and fibrinogen level was 234 mg% (normal, 234-446 mg%). An arterial blood gas obtained on 28% FiO 2 showed a pH of 7.33, PaCO 2 19 mm Hg, PaO 2 of 143 mm Hg, and HCO 3 of 10 mmol/l. Serum electrolytes were remarkable for a potassium of 5.8 mEq/l, carbon dioxide of 16 mEq/l, blood urea nitrogen of 68 mg/dl and creatinine of 2.2 mg/dl. Arterial lactate was elevated at 8.5 mmol/l (normal, 0.3-1.3 mmol/l). Liver function studies were markedly abnormal with a lactate dehydrogenase level of 1142 IU/l, aspartate aminotransferase 1353 IU/l, alkaline phosphatase 99 IU/l, bilirubin 3.4 mg/dl and a serum albumin of 2.3 mg/dl. Serum amylase and lipase levels were normal. Levels of immunoglobulin G were normal. An electrocardiogram showed sinus rhythm at a rate of 100 beats/min with no ischemia.
The chest radiograph revealed bibasilar infiltrates and moderate cardiomegaly. An abdominal X-ray indicated a non-specific bowel gas pattern. Non-contrast computed tomography of the abdomen and pelvis demonstrated thickening of the entire colon, especially the ascending colon, and sludge in the gallbladder but no evidence of the previous appendiceal abscess; minimal bilateral pleural effusions and a small pericardial effusion were also noted. Right upper quadrant ultrasonography revealed a slightly thickened gallbladder wall, mild hepatomegaly and minimal ascites.
The patient's APACHE II (acute physiology and chronic health evaluation II) 12 score was 17 with a predicted mortality rate of 46%. However, using the mortality probability model II (MPM II) 13 developed for critically ill cancer patients admitted to the ICU, the estimated mortality rate for this patient was 92%.
In the ICU, the patient was sedated and intubated for ventilatory support. She was resuscitated with several liters of normal saline. Norepinephrine was used to maintain blood pressure. Intravenous bicarbonate was administered for the unremitting metabolic acidosis. A transthoracic cardiac echocardiogram showed severe left ventricular (LV) dysfunction with an estimated LV ejection fraction (LVEF) of less than 20% and significant mitral and tricuspid regurgitation. Her echocardiogram 6 months before ICU admission showed an LVEF at the lower limit of normal. Dobutamine was added for inotropic support. Fresh frozen plasma and vitamin K were administered for the coagulopathy and packed red cells to treat the anemia. Despite the coagulopathy, there was no evidence of bleeding.
Suspected foci of infection included the abdomen, chest, and the Hickman catheter, which was removed shortly after ICU admission. Broad-spectrum antibiotics empirically administered in the ICU included piperacillin/tazobactam, ciprofloxacin, metronidazole, vancomycin, liposomal amphotericin B, and ganciclovir and one dose of i.v. gamma globulin.
The clinical impression was that of a patient with a very high probability of death suffering from fulminant multiple organ failure and vasodilatory septic shock associated with left ventricular dysfunction. As the patient continued to deteriorate clinically despite the multiple therapeutic modalities in place, a continuous infusion of drotrecogin alfa (activated) was initiated using the approved FDA regimen of 24 g/kg/h at 12 h of ICU admission. The patient was weaned from norepinephrine 8 h into the drotrecogin alfa (activated) infusion. Dobutamine was continued and i.v. diuretics were administered to treat the LV dysfunction. The drotrecogin alfa (activated) infusion was administered for 96 h without interruption.
On ICU day 5, repeat echocardiogram showed significant improvement in LV function with increase in LVEF to 30-35% and dobutamine was discontinued. The coagulopathy resolved and her hepatic and renal function returned to normal with resolution of the metabolic acidosis leading to discontinuation of the bicarbonate infusion. Cultures of the urine, sputum and blood were negative. Blood was negative for cytomegalovirus antigen, hepatitis B surface antigen and hepatitis C antigen. On ICU day 8, the patient was weaned from mechanical ventilation. Within 24 h after extubation, she developed respiratory failure requiring reintubation and reinstitution of ventilator support. The chest radiograph showed increase in bilateral alveolar infiltrates. The patient was vigorously diuresed with marked clinical and radiographic improvement. On ICU day 11, she was again weaned from mechanical ventilation and transferred to the ward on day 14. She was finally discharged home on the 18th hospital day and was doing well with a Karnofsky performance status of 70% 2 weeks later when seen in the outpatient clinic.
Discussion
The high mortality rates of patients who develop severe sepsis or septic shock after HSCT treated with standard therapy and supportive care in the ICU demand that new avenues of treatment be considered for this very high-risk patient population.
Increasing evidence of the importance of sepsis-induced activation of the coagulation system in the pathophysiology of severe sepsis has resulted in clinical trials with novel agents targeting the microvascular injury and coagulopathy in this syndrome. 14, 15 The role of the protein C pathway in sepsis has been extensively reviewed. 7, 8 Activated protein C (APC) is converted from its inactive precursor, protein C, by thrombin in complex with thrombomodulin, an endothelium cell surface protein. The conversion of protein C to APC is impaired during severe sepsis due to down-regulation of thrombomodulin by inflammatory cytokines (TNF-␣, IL-1␤ and IL-6). 7, 8 The efficacy of recombinant human activated protein C (drotrecogin alfa (activated)) in treating adult patients with severe sepsis was recently demonstrated in a multicenter, double-blind, placebo-controlled phase 3 trial. 15 Entry criteria included the presence of a systemic inflammatory response presumed due to infection and at least one associated acute organ dysfunction. Exclusion criteria included patients with a high risk of bleeding, platelet count Ͻ30 000/mm 3 , hypercoagulable states, solid organ or bone marrow transplantation, and moribund patients. There was a significantly lower mortality in patients on drotrecogin alfa (activated) than in patients on placebo (25% vs 31%, P = 0.005). Bleeding was the major side-effect noted in this trial occurring in 3.5% of drotrecogin alfa (activated)-treated patients vs 2% of placebo-treated patients. 15 Based on the findings of this study, the FDA approved drotrecogin alfa (activated) at a fixed dosage of 24 g/kg/h for 96 h for patients with severe sepsis who have a high risk of death.
Although the specific mechanisms by which drotrecogin alfa (activated) exerts its positive effect in severe sepsis are incompletely understood, the biological evaluation suggests that drotrecogin alfa (activated) decreases inflammatory and coagulation system abnormalities as evidenced by the reductions in IL-6 and D-dimer levels, respectively. 14, 15 Patients undergoing HSCT develop a hypercoagulable state characterized by deficiencies in circulating protein C and antithrombin III, as well as increases in IL-6 levels, both of which are associated with development of organ dysfunction and a negative outcome. [16] [17] [18] It is tempting to postulate that low levels of APC and increased levels of IL-6 in patients undergoing HSCT predispose these patients to complications of severe sepsis and multiple organ failure. Thus, treatment with APC may provide potential survival benefit. Levels of APC and IL-6 were not measured in our case.
Commonly, the ICU clinician is faced with treating sepsis of unclear etiology. The inability to definitively determine the site of infection and to obtain positive blood cultures, however, should not preclude treating patients with severe sepsis. In 20-30% of septic patients, a definite site of infection is not determined. 19, 20 Similarly, blood cultures are positive in only approximately 30-35%. [19] [20] [21] Thus, failure to identify a site of infection and obtain positive blood cultures in our patient were not unexpected.
The administration of drotrecogin alfa (activated) in this case highlights the difficulties that clinicians face when choosing to administer a newly approved agent outside of the recommended indication. First, although our patient met the sepsis inclusion criteria that were used in the phase 3 trial, she would have been ineligible because of her transplant status. However, given her extremely critical condition, a high likelihood of death and the absence of any absolute contraindication (active internal bleeding, recent
Bone Marrow Transplantation or high risk of bleeding, or evidence of hypercoagulability) to receiving drotrecogin alfa (activated), we felt that the administration of this drug was justified and ethical despite the lack of data and clinical experience in this patient population. Fortunately, our patient did not demonstrate any bleeding during or after the drug infusion despite the known bleeding diathesis in HSCT patients and the bleeding complications sometimes associated with drotrecogin alfa (activated). Second, sepsis in association with HSCT is not the same as the well-defined sepsis syndrome observed in the general population. 6 Sepsis in HSCT patients is superimposed on the dynamically evolving phases of the transplant process that include pre-transplant myeloablation, post-transplant neutropenia and immune depression, and finally, the post-engraftment period where a prolonged immunodeficiency state may persist. The dosage schema of drotrecogin alfa (activated) approved by the FDA and used in our patient was developed from 'typical' sepsis patients, and not from experience in transplant patients. This suggests that further study would be required to determine first, whether drotrecogin alfa (activated) works at all in this population, and second, if drotrecogin alfa (activated) does work, what the preferred dosage would be based on the specific phase of the HSCT process and the septic episode.
In conclusion, as this case report illustrates, critical care medicine now offers a radically new, potentially therapeutic, approach for allogeneic HSCT patients with severe sepsis. Clinical trials are warranted to further assess the safety and efficacy of drotrecogin alfa (activated) in patients with severe sepsis after HSCT. Until such trials are performed, the clinician will be faced with the dilemma of whether or not to administer drotrecogin alfa (activated) in patients with severe sepsis following HSCT.
